CEACAM5/CD66e Antibody (487609) [Unconjugated]

HEK293 human embryonic kidney cell line transfected with either (A) human CEACAM-5/CD66e or (B) humanCEACAM-8/CD66b and eGFP was stained with Mouse Anti-Human CEACAM‑5/CD66e Monoclonal Antibody (Catalog # MAB41281) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003).

CEACAM‑5/CD66e was detected in immersion fixed paraffin-embedded sections of human colon using Mouse Anti-Human CEACAM‑5/CD66e Monoclonal Antibody (Catalog # MAB41281) at 10 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Hu
• Applications: WB, Flow, IHC, CyTOF-ready
• Clone: 487609
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

CEACAM5/CD66e Antibody (487609) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human CEACAM‑5/CD66e
  Lys35-Ala685
  Accession # ABM87752
• Specificity: Detects human CEACAM‑5/CD66e in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human CEACAM-1 or -6 is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: CEACAM5
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunohistochemistry 8-25 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CEACAM5/CD66e Antibody (487609) [Unconjugated]

• Carcinoembryonic antigen
• carcinoembryonic antigen-related cell adhesion molecule 5
• CD66e antigen
• CD66e
• CEA
• CEACAM5
• CEACAM-5
• CEACD66e
• DKFZp781M2392
• Meconium antigen 100

Background

CEACAM-5, also known as CEA and CD66e, belongs to the large family of CEACAM and pregnancy specific glycoproteins. CEACAM molecules are either transmembrane or GPI-linked, and are differentially expressed between species (1, 2). Orthologs of human CEACAM‑5 have not been described in other species. CEACAM-5, which is expressed primarily by epithelial cells, consists of an N-terminal Ig-like V-set domain followed by six Ig-like C2-set domains and a GPI anchor (2‑4). CEACAM-5 is synthesized as a 180 kDa, variably glycosylated molecule of which approximately 60% is carbohydrate (5). CEACAM-5 functions as a calcium‑independent adhesion molecule through homophilic and heterophilic interactions with CEACAM-1 (6‑8). CEACAM-5 is restricted to the apical face of intestinal epithelial cells in the adult but is more diffuse during embryonic development and in tumors (7). This is consistent with a role in the development and maintenance of epithelial architecture. CEACAM-5 is upregulated in a wide variety of human tumors and is a commonly used cancer marker (9). It promotes tumor cell migration, invasion, adhesion, and metastasis (10). It also contributes to tumor formation by maintaining cellular proliferation in the presence of differentiation stimuli, and by blocking apoptosis following loss of ECM anchorage (anoikis) (11, 12). The GPI anchoring of CEACAM-5 can be released by GPI-PLD, resulting in a soluble molecule that also promotes tumor metastasis (13). Cell surface expression of CEACAM-5 on tumor cells prevents the adhesion of CEACAM-1 expressing NK cells and provides protection from NK‑mediated lysis (6). CEACAM-5 also binds a subset of Neisseria opacity proteins (Opa) and E. coli adhesion proteins (14‑16). These interactions trigger clustering of the lipid raft-localized CEACAM-5 to sites of pathogen contact (15, 16).

1. Zebhauser, R. et al. (2005) Genomics 86:566.
2. Hammarstrom, S. (1999) Semin. Cancer Biol. 9:67.
3. Schrewe H. et al. (1990) Mol. Cell. Biol. 10:2738.
4. Hefta, S.A. et al. (1988) Proc. Natl. Acad. Sci. 85:4648.
5. Garcia, M. et al. (1991) Cancer Res. 51:5679.
6. Stern, N. et al. (2005) J. Immunol. 174:6692.
7. Benchimol, S. et al. (1989) Cell 57:327.
8. Zhou, H. et al. (1993) J. Cell Biol. 122:951.
9. Goldenberg, D.M. et al. (1976) J. Natl. Cancer Inst. 57:11.
10. Blumenthal, R.D. et al. (2005) Cancer Res. 65:8809.
11. Screaton, R.A. et al. (1997) J. Cell Biol. 137:939.
12. Ordonez, C. et al. (2000) Cancer Res. 60:3419.
13. Yamamoto, Y. et al. (2005) Biochem. Biophys. Res. Commun. 333:223.
14. Chen, T. et al. (1997) J. Exp. Med. 185:1557.
15. Bos, M.P. et al. (1997) Infect. Immun. 65:2353.
16. Berger, C.N. et al. (2004) Mol. Microbiol. 52:963.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CEACAM5/CD66e Antibody (MAB41281)(3)

Publications using MAB41281

• Zhao, Y;Zhou, R;Xie, B;Liu, CY;Kalski, M;Cham, CM;Koval, J;Weber, CR;Rubin, DT;Sogin, M;Crosson, S;Huang, J;Fiebig, A;Dalal, S;Chang, EB;Basu, A;Pott, S; Multiomic analysis reveals cellular and epigenetic plasticity in intestinal pouches of ulcerative colitis patients medRxiv : the preprint server for health sciences 2023-11-13 [PMID: 38014192] (IHC, Human)
• M Yarchoan, CY Huang, Q Zhu, AK Ferguson, JN Durham, RA Anders, ED Thompson, NS Rozich, DL Thomas, JM Nauroth, C Rodriguez, A Osipov, A De Jesus-A, DT Le, AG Murphy, D Laheru, RC Donehower, EM Jaffee, L Zheng, NS Azad A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer Cancer Med, 2019-12-26;0(0):. 2019-12-26 [PMID: 31876399] (ELISA Control, Human)
• Jorgensen MM, Baek R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles 1/1/2015 [PMID: 25862471]

Bioinformatics

• Gene Symbol: CEACAM5
• Uniprot:
  • ABM87752()